Discover an exciting investment opportunity in the pharmaceutical industry. A-Synaptic’s patented transdermal drug delivery technology can deliver CBD and THC directly into the bloodstream, bypassing liver toxicity risks associated with oral delivery. By using the FDA’s 505(b)(2) approval pathway and the proven success of GW Pharma’s orally delivered CBD product, Epidiolex used to treat childhood epilepsy, investors can expect a potentially less risky investment opportunity with significant upside potential. Epidiolex annual sales are currently $800 million and expected to grow to $1.5 billion by 2025. This provides A – Synaptic with a very large market opportunity.
The webinar will cover the following topics:
- The prevalence of epilepsy in the USA: There are 500,000 epileptic children and 3 million epileptic adults in the country.
- The success of Epidiolex: GW Pharma’s orally delivered CBD product has proven to be a highly effective treatment for childhood epilepsy. Despite the liver toxicity risks involved, it quickly became a financial success with sales now over $800 million annually.
- A-Synaptic’s transdermal drug delivery technology: The company has recently published human trial results that show its patented technology can deliver CBD and THC directly through all the various layers of skin tissue deep into the bloodstream. This eliminates liver toxicity issues related to oral delivery of CBD and allows for significantly less drug to be used.
- The FDA’s 505(b)(2) approval process: A-Synaptic will be using this shortened and less capital intensive approval pathway that requires a previously approved “predicate” product to be in place. Epidiolex is that predicate product.
- A-Synaptic’s opportunity for investors: The combination of A-Synaptic’s delivery technology and the FDA’s shortened approval pathway creates an opportunity with less risk than a traditional clinical stage pharma investment, while providing the same upside potential.
For more information please contact Matthew T. Sheridan at Matthew@SpotlightFamilyOffice.com